Victory Square Technologies Reports Q3 2025 Financial Results & Provides Corporate Update

Executive Summary

• Victory Square Technologies reported Q3 2025 Adjusted Revenue of $12.83 M (GAAP $10.52 M) and Adjusted EBITDA of $1.26 M, with cash & marketable securities of $25.91 M at quarter‑end.
• Hydreight Technologies, the flagship digital‑health subsidiary, delivered a fourth consecutive profitable quarter, more than doubled year‑over‑year revenues, and held $18.64 M in cash supporting national expansion.
• The Company announced ongoing initiatives across its five platform verticals (digital health, biotech, pet wellness, climate tech, immersive tech), including a $10 M Digital Health & Longevity Accelerator, preclinical work on oral insulin, a new $10 M venture fund for pet‑health startups, and expanded XR health IP development.

Key Details

• Financial Highlights – Q3 2025 (Three months ended Sep 30, 2025)
• Adjusted Revenue: $12.83 M
• GAAP Revenue: $10.52 M
• Gross Margin: $2.33 M
• Adjusted EBITDA: $1.26 M

• Cash & Marketable Securities: $25.91 M

• Financial Highlights – Nine months ended Sep 30, 2025

• Adjusted Revenue: $26.71 M

• GAAP Revenue: $20.44 M

• Hydreight Technologies (Digital Health)

• Year‑over‑year revenue more than doubled vs. Q3 2024.
• Fourth consecutive profitable quarter.
• Internal forecast of ≈1.3 M product orders for FY 2025.
• 1,100+ licenses sold across multiple categories.
• Cash balance at quarter‑end: $18.64 M.

• Operates a nationwide clinical network covering all 50 U.S. states.

• Digital Health & Longevity Accelerator – Launched Jan 2025 with $10 M capital to incubate DTC health companies on the VSDHOne platform (focus areas: biomarkers, tele‑pharmacy, dermatology, GLP‑1, TRT, longevity).

• Insu Therapeutics (Biotech)

• Ongoing preclinical work on oral insulin tablet.

• Pursuing FDA 505(b)(2) pathway; first‑in‑human studies targeted for 2026 pending regulatory review.

• Pawsible Ventures (Pet Health)

• Launched a $10 M venture fund and studio to support 15–20 pet‑health companies over three years (software, diagnostics, AI tools, supplements).

• XR Immersive Tech – Expanding health‑related IP: digital twins for metabolic tracking, 3D biomarker visualization, immersive patient education, virtual onboarding for weight‑loss/hormone programs.

• SafeTest Diagnósticos (Brazil) – Continuing expansion in Brazil’s $15 B diagnostics market with at‑home testing and tele‑health services.

• Capital Recycling & Allocation

• Recent disposals: AI fintech tools to Yocale.ai; BlockX to Edge Total Intelligence.

• Normal Course Issuer Bid (NCIB) announced Sep 22, 2025 – up to 5,000,000 common shares may be repurchased.

• Outlook & Priorities (Q4 2025 / 2026)

• Continue supporting Hydreight/VSDHOne platform growth.
• Advance Insu’s oral insulin program.
• Deploy Pawsible fund and studio initiatives.
• Further develop XR health‑tech tools.
• Ongoing NCIB activity and selective capital recycling.

Notable Quotes

• “Q3 was another quarter of focused execution across our portfolio… These developments reinforce our long-term strategy and the core verticals where we see significant opportunity for value creation.” – Shafin Diamond Tejani, CEO & Chairman, Victory Square Technologies Inc.
• “We remain focused on execution within each platform… Our goal is to build long‑term, sustainable value by supporting companies aligned with our core sectors.” – Shafin Diamond Tejani

All forward‑looking statements are subject to risks and uncertainties; actual results may differ materially.